Advanced in Papillary Thyroid Cancer

Ouchen C. Wang

Pr, 
Wenzhou, CN 
Advanced in Papillary Thyroid Cancer
Pr, 
Wenzhou, CN 
OverviewLocationsClinical Research

Overview

Ouchen Wang practices in Wenzhou, China. Wang is rated as an Advanced expert by MediFind in the treatment of Papillary Thyroid Cancer. Their top areas of expertise are Papillary Thyroid Cancer, Thyroid Cancer, Triple-Negative Breast Cancer, Breast Cancer, and Mastectomy.

Their clinical research consists of co-authoring 61 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 16 articles in the study of Papillary Thyroid Cancer.

Locations

Pr, Wenzhou, China
Other Locations
Nanbai Xiang Street, Wenzhou, 325000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
Enrollment Status: Unknown
Publish Date: April 19, 2017
Intervention Type: Drug
Study Drugs: 5-Fu/Epirubicin/CTX Following Docetaxel, Docetaxel/Capecitabine Followed by Capecitabine/Epirubicin/Cyclophosphamide
Study Phase: Phase 3
View 1 Less Clinical Trial

61 Total Publications

Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial.
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial.
Journal: eLife
Published: April 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile